Ongoing research has led to new therapies — both newly approved and in the pipeline — for patients with HIV infection. Treatment options are rapidly increasing, including new drugs with novel mechanisms, less frequent dosing strategies, long-acting ART, and investigational duotherapies.
In this issue, Dr. Ethel Weld from the Division of Clinical Pharmacology and the Division of Infectious Diseases at Johns Hopkins University School of Medicine explains how the new therapies available or in late-stage development can help clinicians improve their management of their patients infected with the HIV virus.
After participating in this activity, the participant will demonstrate the ability to:
Allison L. Agwu, MD, ScM, FAAP, FIDSA
Associate Professor of Pediatrics and Adult Infectious Diseases
Johns Hopkins University School of Medicine
Alysse G. Wurcel, MD, MS
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Justin Alves, RN, ACRN, CARN
Infectious Disease Associates
Massachusetts General Hospital
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: August 31, 2018
Expiration date: August 30, 2020